股票代码：000999 股票简称：华润三九 编号：2025—053 特此公告。 华润三九医药股份有限公司 华润三九医药股份有限公司 关于高级管理人员离任的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 华润三九医药股份有限公司（以下简称"公司"或"本公司"）董事会于 2025 年 6 月 24 日收到副总裁黄先锋先生提交的辞职报告。黄先锋先生由于工作调整原因，提请 辞去公司副总裁职务，辞职后黄先锋先生继续在公司担任党委专职副书记职务。 黄先锋先生担任副总裁职务的原定任期至公司第九届董事会届满之日止，根据《公 司章程》及有关规定，黄先锋先生辞去公司副总裁职务的申请自辞职报告送达公司董事 会时生效，本次辞职不会影响公司日常经营管理。 截至本公告日，黄先锋先生未持有本公司股票，不存在应履行而未履行的承诺事项。 公司董事会谨对黄先锋先生在担任公司副总裁期间对公司做出的贡献表示衷心感 谢！ 董事会 二○二五年六月二十四日 1 ...

股票代码：000999 股票简称：华润三九 编号：2025—052 华润三九医药股份有限公司 关于控股子公司昆药集团担保事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 一、 担保情况概述 1. 担保事项履行的相关程序 为适应昆药集团及其相关下属公司业务发展需要，满足相关公司融资担保需求，经华润 三九董事会 2025 年第五次会议及 2024 年年度股东会审议通过，2025 年度昆药集团及其下 属子公司预计为昆药集团下属子公司不超过人民币 4.5615 亿元的银行融资授信业务提供连 被担保人：曲靖市康桥医药有限责任公司（以下简称"曲靖康桥"）、昆药商业（昭通） 医药有限公司（以下简称"昭通医药"）。上述被担保人均为华润三九医药股份有限公 司（以下简称"华润三九"）控股子公司昆药集团股份有限公司（以下简称"昆药集团"） 全资子公司昆药集团医药商业有限公司（以下简称"昆药商业"）的控股子公司，不存 在关联担保。 本次担保金额及已实际为其提供的担保余额：本次为上述被担保人提供的担保金额为 1,250 万元，累计已实际为其提供的担保余额为 ...

Core Insights - The "2025 PDI Pharmaceutical R&D and Innovation Conference" has commenced, unveiling the "2025 China Biopharmaceutical R&D Strength Ranking TOP50" and "2025 China Traditional Chinese Medicine R&D Strength Ranking TOP50" [1] - The rankings are initiated by professional organizations like Yaowang Network, which has established a mature and authoritative evaluation system in the pharmaceutical and health industry since its first release in 2016 [1] - Bichang Pharmaceutical, a leading enterprise in traditional Chinese medicine focusing on cardiovascular and cerebrovascular products, has been recognized for its outstanding R&D capabilities [1] Company Overview - Bichang Pharmaceutical has built a sustainable development model centered on R&D, focusing on major diseases and cultivating significant products across various fields including traditional Chinese medicine, chemical drugs, biopharmaceuticals, vaccines, and medical devices [3][4] - The company reported a total sales revenue of 5.83 billion yuan from three proprietary traditional Chinese medicines in the cardiovascular field, which consistently rank among the top 20 in the market share for traditional Chinese medicine in public medical institutions [3] R&D and Product Pipeline - Bichang Pharmaceutical is actively developing 12 biopharmaceutical products, with some entering the NDA application stage, supported by high-level academic platforms such as academician and doctoral workstations [4] - The vaccine segment includes four products, with several others under development, showcasing the company's differentiated competitive edge [4] - The company has a total of 213 products in its pipeline, demonstrating its comprehensive layout and exceptional strength across traditional Chinese medicine, chemical drugs, biopharmaceuticals, and vaccines [4] Financial Performance and Social Responsibility - Since its listing in 2016, Bichang Pharmaceutical has distributed over 7.5 billion yuan in dividends, with an average dividend rate exceeding 85%, reflecting its commitment to shareholder returns and financial resilience [5] - The company has paid nearly 32 billion yuan in taxes and has been actively involved in social welfare projects, significantly contributing to healthcare improvements in remote areas [5] - Bichang Pharmaceutical aims to enhance its R&D investments and contribute to national pharmaceutical advancements and public health, aligning with its philosophy of giving back to society [5]

简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 活配置混合型证券投资基金基金经理(2015年3月16日起至2016年4月22日)、中欧瑾源灵活配置混合型证 券投资基金基金经理(2015年3月31日起至2016年4月22日)、中欧瑾和灵活配置混合型证券投资基金基金 经理(2015年4月13日起至2016年4月22日)。现任中欧医疗健康混合型证券投资基金基金经理(自2016年9 月29日起至今),中欧明睿新起点混合型证券投资基金基金经理(自2018年7月12日起至今)、中欧阿尔法混 合型证券投资基金基金经理(2020年8月20日起至2023年9月28日)。 来源：金融界 金融界2025年6月23日消息，中欧医疗健康混合A(003095) 最新净值1.6675元，增长1.10%。该基金近1个 月收益率1.79%，同类排名725|2535；近3个月收益率5.36%，同类 ...

Investment Rating - The report gives a "Buy" rating for the company, marking the first coverage of the stock [1]. Core Views - The company is positioned as a leading enterprise in the modernization of traditional Chinese medicine, with a strong partnership with China Resources, enhancing its innovation and market capabilities [7][18]. - The core product portfolio remains solid, with innovative research and development in traditional Chinese medicine and secondary development of existing products expected to yield significant growth [7][44]. - The biopharmaceutical and chemical drug segments are gradually improving, with the company focusing on its strengths to enhance efficiency and profitability [7][34]. - The earnings forecast for the company indicates a net profit of 11.52 billion, 13.35 billion, and 15.03 billion yuan for 2025, 2026, and 2027 respectively, with a corresponding PE ratio below the average of comparable companies [7][44]. Summary by Sections Company Overview - Established in 1994, the company has focused on developing modern traditional Chinese medicine and has a significant presence in various therapeutic areas, including cardiovascular, digestive metabolism, and oncology [13][14]. Strategic Partnership - The acquisition of a 28% stake by China Resources enhances the company's capabilities in brand building and market expansion, particularly in outpatient markets [7][18]. Product Development - The company has a robust pipeline of innovative products, with 22 products in clinical II and III phases as of 2024, laying a strong foundation for long-term growth [7][21][26]. Financial Performance - The company’s revenue for 2024 is projected at 84.98 billion yuan, with a slight decline, but a return to growth is expected in 2025 [34][39]. - The net profit is expected to rebound, with a gradual improvement in profit margins due to a focus on core pharmaceutical operations [38][42]. Market Position - The cardiovascular drug market is substantial, with the company maintaining a strong position through its flagship products, such as Compound Danshen Dripping Pills, which have shown stable sales growth [44][52].

Core Viewpoint - The sudden resignation of Xiao Wei as the chairman of Kangyuan Pharmaceutical raises questions about the company's future direction amid declining performance [2][5]. Group 1: Company Leadership Changes - Xiao Wei, the founder and actual controller of Kangyuan Pharmaceutical, has resigned as chairman but will continue to serve as a board member and in other roles [2][5]. - His resignation is attributed to personal reasons, and it is stated that it will not affect the normal operation of the board [5][6]. - Xiao Wei has been a significant figure in the company since its inception, leading its transformation towards modernization and innovation [5][6]. Group 2: Financial Performance - In 2024, Kangyuan Pharmaceutical experienced a significant decline in performance, with revenue dropping by 19.86% to 3.898 billion yuan and net profit decreasing by 15.58% to 392 million yuan [3][8]. - The downward trend continued into the first quarter of 2025, with revenue falling by 35.38% and net profit declining by 38.37% compared to the previous year [3][8]. Group 3: Stock Incentive Plan - Due to unmet performance targets for 2024, Kangyuan Pharmaceutical decided to repurchase and cancel 3.3003 million shares of restricted stock from 155 incentive plan participants [9]. Group 4: Industry Context - There has been a trend of state-owned enterprises acquiring private traditional Chinese medicine companies, with several recent examples [10][11]. - The stock price of Kangyuan Pharmaceutical was reported at 14.73 yuan per share, with a market capitalization of 8.34 billion yuan as of June 20 [13].

Group 1: Company Strategy and Development - The company plans to continue its dual-driven approach of internal and external growth through mergers and acquisitions, focusing on strategic emerging industries and brand assets [2][4] - The company aims to exceed its "14th Five-Year Plan" revenue doubling target, with expectations for an aggressive "15th Five-Year Plan" that emphasizes competitiveness and innovation [6] - The collaboration between Huaren Sanjiu, Tianshili, and Kunyu Group is expected to enhance their market positions, with a clear vision for future development [4] Group 2: Product Development and Market Response - The company is closely monitoring respiratory disease incidence rates, maintaining its market outlook for respiratory products, and expanding its product range [5] - New products like 999 Yiqi Qingfei Granules have been approved to address recovery symptoms from severe respiratory illnesses, filling a market gap [5] - The company is adapting to retail market pressures while maintaining a long-term growth outlook, emphasizing the importance of digital transformation and consumer trust in product quality [10] Group 3: Financial Performance and Shareholder Engagement - The company has consistently increased its cash dividend payout ratio, currently stabilizing between 40%-50% [8] - Future stock incentive plans are being considered as part of state-owned enterprise reforms, aiming to enhance shareholder satisfaction [7] - The company has performed well in state-owned enterprise reform evaluations, indicating strong market management [7] Group 4: Sales and Marketing Strategy - The sales expense ratio is expected to stabilize as the company’s CHC and prescription drug businesses align their sales models [11] - The company anticipates a gradual decrease in sales expense ratios due to the implementation of centralized procurement policies [11]

1. Report Industry Investment Rating No information provided in the given content. 2. Core Viewpoints of the Report - The global economy and financial markets are being significantly influenced by geopolitical tensions, central bank policies, and macroeconomic data [2][13][18] - The commodity market, especially the energy and metal sectors, is experiencing price fluctuations due to geopolitical risks and supply - demand dynamics [2][3] - The bond market shows a complex situation with different trends in yields and prices, affected by factors like credit supply - demand and central bank operations [21][26] - The stock market has seen declines in both A - shares and Hong Kong stocks, with individual stocks and sectors performing differently [29][30] 3. Summary by Relevant Catalogs 3.1 Macro Data - GDP in Q1 2025 grew at a 5.4% year - on - year rate, unchanged from the previous quarter but up from 5.3% in the same period last year [1] - In May 2025, the manufacturing PMI was 49.5%, up from 49.0% in the previous month, while the non - manufacturing PMI for business activities was 50.3%, down from 50.4% [1] - Social financing scale in May 2025 was 22871.00 billion yuan, up from 11591.00 billion yuan in the previous month [1] - CPI in May 2025 was - 0.1% year - on - year, unchanged from the previous month but down from 0.3% in the same period last year; PPI was - 3.3% year - on - year, down from - 2.7% [1] 3.2 Commodity Investment 3.2.1 Comprehensive - Trump criticized Fed Chair Powell, believing that the Fed should have cut interest rates by 2.5 percentage points, which could save billions on short - term debt [2] - Due to the tense situation in the Middle East, Brent crude futures have an implied geopolitical risk premium of about $8/barrel, which may expand if the US intervenes [2] 3.2.2 Metals - China is accelerating the review of rare - earth export license applications and has approved a certain number of compliant applications [3] - 95% of respondents expect global central banks to increase their gold reserves in the next 12 months, and UBS expects the gold price to reach about $3500/ounce by the end of this year [3] - Silver prices have risen by over 11% since June, breaking a 13 - year high, driven by industrial demand recovery [3] 3.2.3 Coal, Coke, Steel, and Minerals - Canada will take additional tariff measures to address overcapacity and unfair trade in the steel and aluminum industries [6] - First Quantum is preparing to ship copper from its Panama mine [6] - Indonesia is strengthening its steel industry by focusing on stainless - steel production in the oil and gas field [6] 3.2.4 Energy and Chemicals - OPEC Secretary - General said that global oil demand remains resilient and will be an important part of the energy structure in the next two decades [7] - Different institutions have different forecasts for oil prices under different scenarios of Iranian oil supply disruptions [9] 3.2.5 Agricultural Products - The global cotton market may see a large - scale increase in production, which may put pressure on cotton prices when new flowers are listed in October [10] - The large - scale wheat harvest in China's "Three Summers" is basically over, with a 96% harvest progress as of June 18 [10] 3.3 Financial News 3.3.1 Open Market - On June 19, the central bank conducted 2035 billion yuan of 7 - day reverse repurchase operations, with a net investment of 842 billion yuan [12] 3.3.2 Key News - China's President Xi Jinping proposed four points on the Middle East situation during a call with Russia's President Putin [13] - Trump has approved an attack plan on Iran but has not issued a final order yet [13] - The central bank of some European countries cut interest rates, while the US and UK maintained their rates [18] 3.3.3 Bond Market - Bank - to - bank main interest - rate bonds' yields mostly rose, and treasury - bond futures showed a differentiated trend [21] - Exchange - traded bonds had different price movements, with some rising and some falling [21] 3.3.4 Foreign Exchange Market - The on - shore RMB against the US dollar closed down 14 points, while the central parity rate was up 32 points [25] - The US dollar index fell 0.12%, and non - US currencies showed mixed performance [25] 3.3.5 Research Report Highlights - CITIC Securities believes that the credit - bond market has a prominent performance, and short - end coupon assets are preferred [26] - Huatai Securities suggests a "high - odds + left - hand + trading - oriented" allocation strategy [27] 3.4 Stock Market - On Thursday, A - shares fell unilaterally, with over 4600 stocks declining, while oil and gas stocks and solid - state battery concepts rose [29] - The Hong Kong Hang Seng Index fell 1.99%, and the Hang Seng Tech Index fell 2.42% [30] - Bubble Mart's stock price fell over 5% on June 19 due to a slump in the secondary market of its Labubu series [31]

Report Industry Investment Rating No relevant content provided. Core Viewpoints The report comprehensively presents the overnight market trends of domestic and international futures, important macro - economic and geopolitical news, and the performance of various financial markets. It also outlines upcoming economic data releases and events, highlighting the complex and dynamic nature of the global economic and financial landscape, especially under the influence of geopolitical tensions in the Middle East and central bank policies [2][3][6]. Summary by Directory Overnight Night - Market Trends - Domestic futures: PTA and PX rose over 3%, SC crude oil, fuel oil, etc. rose over 2%;沪锡,烧碱,沪银 fell over 1% [2] - International oil prices: WTI crude oil rose 0.52% to $73.88/barrel, Brent crude oil rose 2.66% to $78.74/barrel [3] - International precious metals: COMEX gold futures fell 0.61% to $3387.4/ounce, COMEX silver futures fell 1.5% to $36.36/ounce [4] - London base metals: Most fell, LME aluminum fell 0.84%, LME tin fell 0.79%, LME copper fell 0.37%, LME zinc rose 0.38% [4] Important Information Macro Information - Geopolitical events: China called for a cease - fire in the Middle East conflict; the Iranian reactor was attacked; Iran responded to US threat; Trump criticized Powell; EU may accept 10% "reciprocal" tariff; Zelensky was ready to meet Putin; Israel aimed to eliminate Khamenei [6][7][8] Energy and Chemical Futures - Inventory changes: Glass inventory rose 0.29% to 6988.7 million heavy boxes; paper pulp inventory rose 1.1% to 220.8 million tons; Singapore fuel oil inventory fell to a 5 - week low; domestic soda ash inventory rose 2.40%; East China methanol inventory fell 2.71 million tons [12][13][14] Metal Futures - Lithium carbonate auction: 300 tons each of Ronghui and Yongshan lithium carbonate were auctioned at 59910 yuan/ton and 60010 yuan/ton respectively [16] - Photovoltaic industry: Planned to cut production by 10% - 15% in Q3 and implement strict price - protection policies [18] Black - Series Futures - Silicon manganese pricing: HeSteel Group set the June silicon manganese price at 5650 yuan/ton [21] - Steel product data: Rebar production increased 2.22%, factory inventory decreased for the fourth week, social inventory decreased for the fifteenth week, and apparent demand decreased for the third week [21] Agricultural Futures - Sugar export: The number of ships waiting to load sugar in Brazilian ports decreased, and the waiting sugar volume decreased to 285.39 million tons [24] - Pig data: The average live - weight of national outer - ternary pigs decreased to 123.78 kg, a 3 - month low [25] - Canadian rapeseed: Export volume decreased 17.05% to 13.14 million tons in the week ending June 15 [25] Financial Markets Financial - A - shares and Hong Kong stocks: A - shares fell, with over 4600 stocks declining; Hong Kong stocks also fell, and Southbound funds had net purchases of HK$1427 million [27] - ESG action: The Shanghai Stock Exchange launched a special action plan to improve ESG ratings of listed companies [29] - IPO situation: There were over 160 companies queuing for IPO in Hong Kong, and 40+ filed in May [29] Industry - New energy vehicles: Three departments studied new energy vehicle safety management, emphasizing no "involution" competition [30] - Photovoltaic industry: Planned for deeper production cuts in Q3 and implemented strict price - protection policies [30] - Real estate: Guangzhou continued to purchase existing housing as resettlement housing; Xi'an introduced new housing policies [32] Overseas - US politics and economy: Trump criticized Powell; the US Senate postponed sanctions on Russia; Zelensky wanted to meet Putin; multiple central banks adjusted interest rates [33][34][36] - Trade issues: The EU tried to reach a trade deal with the US; Canada planned tariff measures [36] - Global investment: Global FDI decreased 11% in 2024, with Europe down 58%; Asia attracted $605 billion [37] International Stock Markets - US stocks: Closed on June 19 for Juneteenth [41] - European stocks: Fell due to Middle East geopolitical risks and Fed policies [41] - US retail investors: Bullish sentiment decreased, and bearish sentiment increased [41] Commodities - Crude oil: International oil prices rose, with a geopolitical risk premium of about $8/barrel in Brent crude [44] - Precious metals: International precious metals futures fell, affected by Fed policies [44] - Base metals: Most London base metals fell, influenced by supply - demand and Fed policies [45] Bonds - Domestic bonds: Yields of domestic inter - bank bonds mostly rose, and bond ETF support measures were studied [46][48] - International bonds: European bond yields rose due to geopolitical risks and market sentiment [48] Foreign Exchange - Hong Kong dollar: The Hong Kong Monetary Authority warned of potential weakening of the Hong Kong dollar [49] - RMB: The RMB's global payment share decreased in May; on - shore and off - shore RMB had different performances [50][52] - US dollar: The US dollar index fluctuated, affected by Fed policies and market sentiment [52] Upcoming Economic Data and Events - Economic data: Include UK consumer confidence, Japanese CPI, Chinese LPR, etc. [55] - Events: Include Japanese and Chinese central bank operations, speeches by central bank governors, etc. [57]

Group 1 - The price of silver futures has surpassed that of gold, with silver futures on COMEX rising over 25% year-to-date, while platinum futures on NYMEX have increased over 45% [1] - The Ministry of Commerce of China is expediting the review of rare earth export license applications and has approved a certain number of compliant applications [1] - The Ministry of Industry and Information Technology and other departments are focusing on the safety management of new energy vehicles, urging manufacturers to guide consumers in proper vehicle usage and avoid exaggerated claims [1] Group 2 - The Beijing Municipal Committee has issued support measures for the high-quality development of the gaming and esports industry, offering rewards up to 30 million yuan for eligible projects [2] - The Hong Kong Stock Exchange has over 160 companies queued for IPOs, with more than 40 applications submitted in May alone [2] - The A-share market experienced a decline, with over 4,600 stocks falling, while the Shanghai Composite Index closed down 0.79% at 3,362.11 points [2] Group 3 - Morgan Stanley has updated its focus stock list for Hong Kong and Chinese concept stocks, removing Pop Mart and adding China Pacific Insurance [3] - Yushutech has completed a Series C financing round with a pre-investment valuation exceeding 10 billion yuan [3] - Guosen Securities' acquisition of 96.08% of Wanhe Securities has been approved by the Shenzhen Stock Exchange's merger and reorganization review committee [3] Group 4 - Zhongyan Chemical plans to approve a capital reduction for its subsidiary, which is expected to constitute a major asset restructuring [4] - Keda New Materials intends to acquire at least 51% of Zhongke Huami's equity to expand into the semiconductor integrated circuit field [5] - CloudWalk Technology's multi-modal AI technology can be applied to stablecoin wallet scenarios [6] Group 5 - Saint Noble Bio expects a net profit of 77.03 million to 94.14 million yuan for the first half of the year, representing a year-on-year increase of 253.54% to 332.10% due to strong performance in its peptide raw material business [6] - Haitian Flavoring has successfully listed its H-shares on the Hong Kong Stock Exchange [6]